The George Group - Pharmacogenomic Technologies

Dr Amee George. Image: The ANU Centre for Therapeutic Discovery  Dr Amee George at The ANU Centre for Therapeutic Discovery

Dr Amee George leads a specific research program into disorders of ribosome biogenesis (ribosomopathies) and the molecular mechanism(s) and signalling pathways which link this process to the nucleolus, a key structure in ribosome biogenesis. She is also a national specialist in high-throughput and high-content screening, leading the ANU Centre for Therapeutic Discovery.

Closely collaborating with the Hannan Group, the George Group has a research interest in:

  • identifying disease biomarkers (genotype-phenotype) and therapeutic targets for drug discovery,
  • utilising functional (RNAi/CRISPR) and molecule/biologic approaches and high-content imaging readouts
  • developing new approaches to model disease in vitro, with a view to use these models for drug discovery projects (including complex 2D and 3D cellular models).




Research support officer


Filter by keyword

1.    Hannan KM, Soo P, Wong MS, Lee JK, Hein N, Poh P, et al. Nuclear stabilization of p53 requires a functional nucleolar surveillance pathway. CELL REPORTS. 2022;41(5).
2.    Gauthier-Coles G, Broer A, McLeod MD, George AJ, Hannan RD, Broer S. Identification and characterization of a novel SNAT2 (SLC38A2) inhibitor reveals synergy with glucose transport inhibition in cancer cells. FRONTIERS IN PHARMACOLOGY. 2022;13.
3.    Hicks SM, Pohl K, Neeman T, McNamara HA, Parsons KM, He JS, et al. A Dual-Antigen Enzyme-Linked Immunosorbent Assay Allows the Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in a Low-Transmission Setting. JOURNAL OF INFECTIOUS DISEASES. 2021;223(1):10-4.
4.    Chin CV, Antony J, Ketharnathan S, Labudina A, Gimenez G, Parsons KM, et al. Cohesin mutations are synthetic lethal with stimulation of WNT signaling. ELIFE. 2020;9.
5.    Chan KT, Blake S, Zhu HR, Kang J, Trigos AS, Madhamshettiwar PB, et al. A functional genetic screen defines the AKT-induced senescence signaling network. CELL DEATH AND DIFFERENTIATION. 2020;27(2):725-41.
6.    Chin CV, Antony J, George AJ, He JS, Parson K, Hannan RD, et al. A synthetic lethal drug screen identifies exploitable vulnerabilities in cohesin-deficient cells. MOLECULAR CANCER THERAPEUTICS. 2019;18(12).
7.    Villacis LN, Wong MS, Ferguson LL, Hein N, George AJ, Hannan KM. New Roles for the Nucleolus in Health and Disease. BIOESSAYS. 2018;40(5).
8.    Villacis LN, Al-Obaidi SJ, Madhamshettiwar P, Hein N, Chen J, Soo P, et al. A High-Throughput Screening Approach to Identify Therapeutics for the Treatment of Diamond-Blackfan Anaemia. BLOOD. 2018;132.
9.    He JS, Soo P, Evers M, Parsons KM, Hein N, Hannan KM, et al. High-Content Imaging Approaches to Quantitate Stress-Induced Changes in Nucleolar Morphology. ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES. 2018;16(6):320-32.
10.    Chen J, Siva K, Rzymski T, Johansson L, Lundback T, Villacis LN, et al. Small Molecule Screens Identify CDK8-Inhibitors As Candidate Diamond-Blackfan Anemia Drugs. BLOOD. 2018;132.
11.    Venugopal P, Moore S, Lawrence DM, George AJ, Hannan RD, Bray SCE, et al. Self-reverting mutations partially correct the blood phenotype in a Diamond Blackfan anemia patient. HAEMATOLOGICA. 2017;102(12):506-9.
12.    Hein N, Cameron DP, Hannan KM, Nguyen NYN, Fong CY, Sornkom J, et al. Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population. BLOOD. 2017;129(21):2882-95.
13.    George AJ, Allen A, Chand AL. Repurposing ARBs as treatments for breast cancer. AGING-US. 2017;9(5):1357-8.
14.    Coulson R, Liew SH, Connelly AA, Yee NS, Deb S, Kumar B, et al. The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma. ONCOTARGET. 2017;8(12):18640-56.
15.    Quin J, Chan KT, Devlin JR, Cameron DP, Diesch J, Cullinane C, et al. Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling. ONCOTARGET. 2016;7(31):49800-18.
16.    Devlin JR, Hannan KM, Hein N, Cullinane C, Kusnadi E, Ng PY, et al. Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma. CANCER DISCOVERY. 2016;6(1):59-70.
17.    Chan KT, Paavolainen L, Hannan KM, George AJ, Hannan RD, Simpson KJ, et al. Combining High-Content Imaging and Phenotypic Classification Analysis of Senescence-Associated Beta-Galactosidase Staining to Identify Regulators of Oncogene-Induced Senescence. ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES. 2016;14(7):416-28.
18.    Sjogren SE, Siva K, Soneji S, George AJ, Winkler M, Jaako P, et al. Glucocorticoids improve erythroid progenitor maintenance and dampen Trp53 response in a mouse model of Diamond-Blackfan anaemia. BRITISH JOURNAL OF HAEMATOLOGY. 2015;171(4):517-29.
19.    Hein N, Hannan KM, George AJ, Sanij E, Hannan RD. The nucleolus: an emerging target for cancer therapy. TRENDS IN MOLECULAR MEDICINE. 2013;19(11):643-54.
20.    George AJ, Purdue BW, Gould CM, Thomas DW, Handoko Y, Qian HW, et al. A functional siRNA screen identifies genes modulating angiotensin II-mediated EGFR transactivation. JOURNAL OF CELL SCIENCE. 2013;126(23):5377-90.
21.    George AJ, Hannan RD, Thomas WG. Unravelling the molecular complexity of GPCR-mediated EGFR transactivation using functional genomics approaches. FEBS JOURNAL. 2013;280(21):5258-68.
22.    Wong LH, McGhie JD, Sim M, Anderson MA, Ahn S, Hannan RD, et al. ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells. GENOME RESEARCH. 2010;20(3):351-60.
23.    George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: old dog, new tricks. NATURE REVIEWS CANCER. 2010;10(11):745-59.
24.    George AJ, Gordon L, Beissbarth T, Koukoulas I, Holsinger RMD, Perreau V, et al. A Serial Analysis of Gene Expression Profile of the Alzheimer's Disease Tg2576 Mouse Model. NEUROTOXICITY RESEARCH. 2010;17(4):360-79.
25.    Petratos S, Li QX, George AJ, Hou X, Kerr ML, Unabia SE, et al. The beta-amyloid protein of Alzheimers disease increases neuronal CRMP-2 phosphorylation by a Rho-GTP mechanism. BRAIN. 2008;131:90-108.